Insider Selling: Artivion (NYSE:AORT) EVP Sells 6,316 Shares of Stock

Artivion, Inc. (NYSE:AORT) EVP Lance Berry sold 6,316 shares of Artivion stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $238,618.48. Following the transaction, the executive vice president directly owned 210,827 shares in the company, valued at $7,965,044.06. This trade represents a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Artivion Trading Down 0.5%

Shares of Artivion stock traded down $0.21 on Wednesday, hitting $38.41. The stock had a trading volume of 460,494 shares, compared to its average volume of 509,518. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.25. The stock’s 50-day simple moving average is $41.42 and its two-hundred day simple moving average is $42.92. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of 61.30 and a beta of 1.60.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The company had revenue of $118.30 million during the quarter, compared to analyst estimates of $116.42 million. The company’s revenue was up 19.2% compared to the same quarter last year. As a group, sell-side analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Trading of Artivion

Several institutional investors have recently added to or reduced their stakes in AORT. Verition Fund Management LLC boosted its position in shares of Artivion by 1.6% during the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock valued at $716,000 after buying an additional 274 shares during the last quarter. Entropy Technologies LP raised its position in Artivion by 6.0% in the 4th quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock worth $251,000 after buying an additional 310 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in Artivion by 1.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 23,294 shares of the company’s stock valued at $985,000 after acquiring an additional 414 shares during the period. PNC Financial Services Group Inc. boosted its holdings in shares of Artivion by 6.2% during the 3rd quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock valued at $349,000 after acquiring an additional 477 shares during the last quarter. Finally, Arizona State Retirement System boosted its holdings in shares of Artivion by 4.6% during the 4th quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock valued at $512,000 after acquiring an additional 494 shares during the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on AORT shares. Oppenheimer reiterated an “outperform” rating and issued a $50.00 price target on shares of Artivion in a research note on Friday, November 7th. Canaccord Genuity Group decreased their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Citizens Jmp boosted their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $58.00 target price on shares of Artivion in a research note on Monday, February 2nd. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.97.

Artivion News Summary

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Analysts remain constructive — consensus rating is “Moderate Buy” with several buy/outperform notes and mid‑to‑high price targets that support investor demand. Artivion Receives Consensus Rating
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference (virtual fireside chat), giving the company an opportunity to update investors on growth drivers, product progress and commercial milestones. Conferences can re‑ignite buying interest if guidance or pipeline commentary is favorable. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional investors have been adding exposure (Invesco and others increased stakes), which can provide a steady bid and signals confidence from professional investors. MarketBeat – Artivion Institutional Activity
• Neutral Sentiment: Recent quarterly results beat revenue and EPS estimates and showed strong year‑over‑year revenue growth; that supports the bull case but may already be reflected in the share price and analyst upgrades. MarketBeat – Artivion Earnings Summary
• Negative Sentiment: Multiple senior insiders sold stock over March 2–4 (including the CEO and several EVPs/SVPs). A concentrated block of insider sales often weighs on sentiment even when executives retain large holdings — markets can interpret it as opportunistic liquidity or as a signal of limited near‑term confidence. Insider Trades Alert

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.